04:52 AM EDT, 06/27/2024 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) said Wednesday that a phase 3 trial showed that a greater proportion of children with eosinophilic esophagitis receiving their drug Dupixent showed "significant improvements" in disease measures compared with those that received a placebo.

The results of the trial were published in the New England Journal of Medicine. Data from the trial prompted the US Food and Drug Administration's priority review and approval of the drug, also called dupilumab, in children aged one to 11 years weighing at least 15 kg, as well as the submission that is under review by the European Medicines Agency.

According to the study, a greater proportion of children receiving Dupixent showed remission at 16 weeks, the company said. Those treated with higher doses of Dupixent experienced "significant improvements" in disease severity, with improvements sustained for up to one year, the company said.

Price: 1,065.00, Change: -4.16, Percent Change: -0.39